- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00462579
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
June 11, 2018 updated by: University of Pittsburgh
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use [4], may be transmitted from person to person [5], and may be passed via environmental contamination [6].
Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections.
There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms.
The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.
Study Overview
Status
Completed
Conditions
Detailed Description
The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.he
following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), date of positive culture, prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history.
We will collect information retrospectively.
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
carbapenem-resistant acinetobacter baumannii positive cultures
Description
Inclusion Criteria:
- Positive cultures of carbapenem-resistant acinetobacter baumannii
Exclusion Criteria:
- Not meeting inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
dead or alive
Time Frame: end of study
|
health status
|
end of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David L Paterson, MD, University of Pittsburgh Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2007
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
April 17, 2007
First Submitted That Met QC Criteria
April 18, 2007
First Posted (Estimate)
April 19, 2007
Study Record Updates
Last Update Posted (Actual)
June 12, 2018
Last Update Submitted That Met QC Criteria
June 11, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO07040057
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acinetobacter Infections
-
Entasis TherapeuticsCompletedAcinetobacter Baumannii-calcoaceticus Complex InfectionsUnited States
-
Entasis TherapeuticsCompletedAcinetobacter Baumannii InfectionAustralia
-
Entasis TherapeuticsCompletedAcinetobacter Baumannii-calcoaceticus Complex InfectionsUnited States
-
University of PittsburghCompletedAcinetobacter InfectionsUnited States
-
University Hospital, Strasbourg, FranceRecruitingAcinetobacter BaumanniiFrance
-
Gangnam Severance HospitalCompletedAcinetobacter Infections | Colistin | Rifampin
-
Entasis TherapeuticsCompletedBacteremia | Ventilator-associated Bacterial Pneumonia | Acinetobacter Baumannii-calcoaceticus Complex | Hospital-acquired Bacterial Pneumonia | Colistin Resistant ABCUnited States, Belarus, Brazil, China, Greece, Hungary, India, Israel, Korea, Republic of, Lithuania, Mexico, Peru, Puerto Rico, Russian Federation, Taiwan, Thailand, Turkey
-
Rambam Health Care CampusAssaf-Harofeh Medical Center; Sheba Medical Center; Monaldi Hospital; Rutgers Robert... and other collaboratorsNot yet recruitingCarbapenem Resistant Bacterial Infection | Acinetobacter Bacteremia | Acinetobacter Pneumonia
-
National Taiwan University HospitalFar Eastern Memorial HospitalUnknownAcinetobacter BacteraemiaTaiwan
-
Sutep JaruratanasirikulPrince of Songkla UniversityCompletedAcinetobacter InfectionsThailand